Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome

Katherine Esposito, Miryam Ciotola, Diego Carleo, Bruno Schisano, Franco Saccomanno, Ferdinando Carlo Sasso, Domenico Cozzolino, Roberta Assaloni, Domenico Merante, Antonio Ceriello, Dario Giugliano

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

OBJECTIVE - The aim of this study was to assess the effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. RESEARCH DESIGN AND METHODS - This was a randomized, double-blind, controlled clinical trial. One hundred subjects (54 men and 46 women) with the metabolic syndrome, as defined by the Adult Treatment Panel III, were followed for 12 months after random assignment to rosiglitazone (4 mg/day) or placebo. Primary end points were flow-mediated dilation and high-sensitivity C-reactive protein (hs-CRP) levels; secondary end points were lipid and glucose parameters, homeostasis model assessment (HOMA) of insulin sensitivity, endothelial function score, and circulating levels of interleukin (IL)-6, IL-18, and adiponectin. RESULTS - Compared with 60 control subjects matched for age and sex, patients with the metabolic syndrome had decreased endothelial function, raised concentrations of inflammatory markers, and reduced insulin sensitivity. After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2%, P <0.001) and reduced hs-CRP levels (-0.7 mg/dl, P = 0.04), compared with the placebo group. Moreover, HOMA (-0.8, P = 0.01) and serum concentrations of IL-6 (-0.5 pg/ml, P = 0.045) and IL-18 (-31 pg/ml, P = 0.036) were significantly reduced in subjects receiving rosiglitazone, whereas adiponectin levels showed a significant increment (2.3 μg/ml, P = 0.02). High-density lipoprotein-cholesterol levels increased more and triglyceride levels decreased more in the rosiglitazone group compared with the placebo group. At 1 year of follow-up, 30 subjects receiving rosiglitazone still had features of the metabolic syndrome, compared with 45 subjects receiving placebo (P <0.001). CONCLUSIONS - Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome.

Original languageEnglish
Pages (from-to)1071-1076
Number of pages6
JournalDiabetes Care
Volume29
Issue number5
DOIs
Publication statusPublished - 2006

Fingerprint

rosiglitazone
Placebos
Interleukin-18
Adiponectin
C-Reactive Protein
Insulin Resistance
Interleukin-6
Homeostasis
Controlled Clinical Trials
Vasodilation
HDL Cholesterol
Dilatation
Triglycerides

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Esposito, K., Ciotola, M., Carleo, D., Schisano, B., Saccomanno, F., Sasso, F. C., ... Giugliano, D. (2006). Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care, 29(5), 1071-1076. https://doi.org/10.2337/diacare.2951071

Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. / Esposito, Katherine; Ciotola, Miryam; Carleo, Diego; Schisano, Bruno; Saccomanno, Franco; Sasso, Ferdinando Carlo; Cozzolino, Domenico; Assaloni, Roberta; Merante, Domenico; Ceriello, Antonio; Giugliano, Dario.

In: Diabetes Care, Vol. 29, No. 5, 2006, p. 1071-1076.

Research output: Contribution to journalArticle

Esposito, K, Ciotola, M, Carleo, D, Schisano, B, Saccomanno, F, Sasso, FC, Cozzolino, D, Assaloni, R, Merante, D, Ceriello, A & Giugliano, D 2006, 'Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome', Diabetes Care, vol. 29, no. 5, pp. 1071-1076. https://doi.org/10.2337/diacare.2951071
Esposito, Katherine ; Ciotola, Miryam ; Carleo, Diego ; Schisano, Bruno ; Saccomanno, Franco ; Sasso, Ferdinando Carlo ; Cozzolino, Domenico ; Assaloni, Roberta ; Merante, Domenico ; Ceriello, Antonio ; Giugliano, Dario. / Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. In: Diabetes Care. 2006 ; Vol. 29, No. 5. pp. 1071-1076.
@article{bfa01cc6fe5d4f3ab10166675e75e47f,
title = "Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome",
abstract = "OBJECTIVE - The aim of this study was to assess the effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. RESEARCH DESIGN AND METHODS - This was a randomized, double-blind, controlled clinical trial. One hundred subjects (54 men and 46 women) with the metabolic syndrome, as defined by the Adult Treatment Panel III, were followed for 12 months after random assignment to rosiglitazone (4 mg/day) or placebo. Primary end points were flow-mediated dilation and high-sensitivity C-reactive protein (hs-CRP) levels; secondary end points were lipid and glucose parameters, homeostasis model assessment (HOMA) of insulin sensitivity, endothelial function score, and circulating levels of interleukin (IL)-6, IL-18, and adiponectin. RESULTS - Compared with 60 control subjects matched for age and sex, patients with the metabolic syndrome had decreased endothelial function, raised concentrations of inflammatory markers, and reduced insulin sensitivity. After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2{\%}, P <0.001) and reduced hs-CRP levels (-0.7 mg/dl, P = 0.04), compared with the placebo group. Moreover, HOMA (-0.8, P = 0.01) and serum concentrations of IL-6 (-0.5 pg/ml, P = 0.045) and IL-18 (-31 pg/ml, P = 0.036) were significantly reduced in subjects receiving rosiglitazone, whereas adiponectin levels showed a significant increment (2.3 μg/ml, P = 0.02). High-density lipoprotein-cholesterol levels increased more and triglyceride levels decreased more in the rosiglitazone group compared with the placebo group. At 1 year of follow-up, 30 subjects receiving rosiglitazone still had features of the metabolic syndrome, compared with 45 subjects receiving placebo (P <0.001). CONCLUSIONS - Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome.",
author = "Katherine Esposito and Miryam Ciotola and Diego Carleo and Bruno Schisano and Franco Saccomanno and Sasso, {Ferdinando Carlo} and Domenico Cozzolino and Roberta Assaloni and Domenico Merante and Antonio Ceriello and Dario Giugliano",
year = "2006",
doi = "10.2337/diacare.2951071",
language = "English",
volume = "29",
pages = "1071--1076",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome

AU - Esposito, Katherine

AU - Ciotola, Miryam

AU - Carleo, Diego

AU - Schisano, Bruno

AU - Saccomanno, Franco

AU - Sasso, Ferdinando Carlo

AU - Cozzolino, Domenico

AU - Assaloni, Roberta

AU - Merante, Domenico

AU - Ceriello, Antonio

AU - Giugliano, Dario

PY - 2006

Y1 - 2006

N2 - OBJECTIVE - The aim of this study was to assess the effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. RESEARCH DESIGN AND METHODS - This was a randomized, double-blind, controlled clinical trial. One hundred subjects (54 men and 46 women) with the metabolic syndrome, as defined by the Adult Treatment Panel III, were followed for 12 months after random assignment to rosiglitazone (4 mg/day) or placebo. Primary end points were flow-mediated dilation and high-sensitivity C-reactive protein (hs-CRP) levels; secondary end points were lipid and glucose parameters, homeostasis model assessment (HOMA) of insulin sensitivity, endothelial function score, and circulating levels of interleukin (IL)-6, IL-18, and adiponectin. RESULTS - Compared with 60 control subjects matched for age and sex, patients with the metabolic syndrome had decreased endothelial function, raised concentrations of inflammatory markers, and reduced insulin sensitivity. After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2%, P <0.001) and reduced hs-CRP levels (-0.7 mg/dl, P = 0.04), compared with the placebo group. Moreover, HOMA (-0.8, P = 0.01) and serum concentrations of IL-6 (-0.5 pg/ml, P = 0.045) and IL-18 (-31 pg/ml, P = 0.036) were significantly reduced in subjects receiving rosiglitazone, whereas adiponectin levels showed a significant increment (2.3 μg/ml, P = 0.02). High-density lipoprotein-cholesterol levels increased more and triglyceride levels decreased more in the rosiglitazone group compared with the placebo group. At 1 year of follow-up, 30 subjects receiving rosiglitazone still had features of the metabolic syndrome, compared with 45 subjects receiving placebo (P <0.001). CONCLUSIONS - Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome.

AB - OBJECTIVE - The aim of this study was to assess the effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. RESEARCH DESIGN AND METHODS - This was a randomized, double-blind, controlled clinical trial. One hundred subjects (54 men and 46 women) with the metabolic syndrome, as defined by the Adult Treatment Panel III, were followed for 12 months after random assignment to rosiglitazone (4 mg/day) or placebo. Primary end points were flow-mediated dilation and high-sensitivity C-reactive protein (hs-CRP) levels; secondary end points were lipid and glucose parameters, homeostasis model assessment (HOMA) of insulin sensitivity, endothelial function score, and circulating levels of interleukin (IL)-6, IL-18, and adiponectin. RESULTS - Compared with 60 control subjects matched for age and sex, patients with the metabolic syndrome had decreased endothelial function, raised concentrations of inflammatory markers, and reduced insulin sensitivity. After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2%, P <0.001) and reduced hs-CRP levels (-0.7 mg/dl, P = 0.04), compared with the placebo group. Moreover, HOMA (-0.8, P = 0.01) and serum concentrations of IL-6 (-0.5 pg/ml, P = 0.045) and IL-18 (-31 pg/ml, P = 0.036) were significantly reduced in subjects receiving rosiglitazone, whereas adiponectin levels showed a significant increment (2.3 μg/ml, P = 0.02). High-density lipoprotein-cholesterol levels increased more and triglyceride levels decreased more in the rosiglitazone group compared with the placebo group. At 1 year of follow-up, 30 subjects receiving rosiglitazone still had features of the metabolic syndrome, compared with 45 subjects receiving placebo (P <0.001). CONCLUSIONS - Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=33646694348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646694348&partnerID=8YFLogxK

U2 - 10.2337/diacare.2951071

DO - 10.2337/diacare.2951071

M3 - Article

C2 - 16644639

AN - SCOPUS:33646694348

VL - 29

SP - 1071

EP - 1076

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -